



PRIOR AUTHORIZATION PROGRAM FORM

Olumiant™ (Baricitinib)

Instructions:

1. Section 1 to be completed by Plan Member / Patient
2. Section 2 to be completed by Physician (expenses incurred by the completion of this form is at plan member's expense)
3. Section 3 to be completed by Pharmacist

Please fax completed form to NexgenRx Formulary Management to 1-877-639-4369 or mail to 145 The West Mall P.O. Box 110 U, Toronto, Ontario, M8Z-5M4

Section 1: To be completed by Patient

Member's Name: (Last, First)	Card ID Number:														
Patient's Name: (Last, First)	Patient's Date of Birth (dd/mm/yy)	Relationship to Member (please circle)			PATIENT CODE										
		Employee Spouse Dependent													

Results of this request to be communicated to:

<input type="checkbox"/> Pharmacy	<input type="checkbox"/> Patient / Legal Guardian Named Below	<input type="checkbox"/> email:
-----------------------------------	---	---------------------------------

I authorize NexgenRx Inc. (a) to use the personal information disclosed on this form, and any other personal information known to NexgenRx Inc. regarding the above-named patient, for the purpose of assessing this prior authorization request and any related claim and administering the benefit plan under which any such claim is made, and (b) to contact, and to obtain any such personal information from and to disclose any such personal information to, any physician, pharmacist or other health care professional having knowledge of such patient's health relevant to this request and any related claim.

Patient / Legal Guardian Name: _____ Telephone Number: _____

Signature of Patient/ Legal Guardian: _____ Date (dd/mm/yy): _____

Section 2: To be completed by Physician

Drug Name & Strength:	DIN:	Dosage Instructions:
-----------------------	------	----------------------

Eligibility for drug coverage is dependent upon the patient meeting at least one of the qualifying criteria listed below. If the patient has another drug plan, prior authorization may cover some or all of the excess not paid by the primary plan.

Please indicate if the patient meets the following qualifying criteria for drug coverage:

- Olumiant in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of rheumatoid arthritis (RA), in adult patients with moderately to severely active RA who have had an inadequate response to one or more DMARDs. In cases of intolerance to MTX, physicians may consider the use of Xeljanz as monotherapy.

Limitations of use: Use of Xeljanz in combination with biological DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Physician Name: (Last, First)	License Number:
Address: (Street, City, Province, Postal Code)	Telephone Number : () - Fax Number: () -
Signature of Physician:	Date (dd/mm/yy)

Section 3: To be completed by Pharmacist

Pharmacy Name:	Provider Number:
Pharmacy Address: (Street, City, Province, Postal Code)	Telephone Number : () - Fax Number: () -
Signature of Pharmacist: _____	
Pharmacist's Name: (Print Last, First) _____	

Internal Office Use Only:

Date Received:		Date Approved & By:
----------------	--	---------------------